Cargando…

Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer

BACKGROUND: In patients with hormone receptor-positive (HR+)/premenopausal breast cancer, luteinizing hormone-releasing hormone analogs (LHRHas) are used as standard endocrine treatment. Based on previous clinical studies, 1-month formulations are recommended in most breast cancer treatment guidelin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Zhen-Yu, Lee, Young-jin, Kim, Heejeong, Lee, Jongwon, Chung, Il Yong, Kim, Jisun, Lee, Saebyeol, Son, Byung-Ho, Kim, Sung-Bae, Jeong, Jae Ho, Gong, Gyungyub, Ahn, Sei-Hyun, Ko, BeomSeok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113853/ https://www.ncbi.nlm.nih.gov/pubmed/33996592 http://dx.doi.org/10.3389/fonc.2021.665426

Ejemplares similares

Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen
por: Lee, Young-jin, et al.
Publicado: (2020)

Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty
por: Kim, You Jin, et al.
Publicado: (2013)

Clinical development of the GnRH agonist leuprolide acetate depot
por: Chwalisz, Kristof
Publicado: (2022)

Leuprolide Acetate 1-Month Depot for Central Precocious Puberty: Hormonal Suppression and Recovery
por: Neely, E. Kirk, et al.
Publicado: (2010)

Breast-conserving surgery with 3D-printed surgical guide: a single-center, prospective clinical study
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

Data on distant metastasis and survival after locoregional recurrence following nipple-sparing mastectomy and immediate breast reconstruction
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer
por: Spitz, A, et al.
Publicado: (2012)

Myocardial Infarction in a Premenopausal Woman on Leuprolide Therapy
por: Perez, Irving E., et al.
Publicado: (2015)

Therapeutic Effects of Leuprorelin (Leuprolide Acetate) in Sexual Offenders with Paraphilia
por: Choi, Jong Hyuk, et al.
Publicado: (2018)

Efficacy of Leuprolide Acetate 1-Month Depot for Central Precocious Puberty (CPP): Growth Outcomes During a Prospective, Longitudinal Study
por: Lee, Peter A, et al.
Publicado: (2011)

Treatment with Depot Leuprolide Acetate in Girls with Idiopathic Precocious Puberty: What Parameter should be Used in Deciding on the Initial Dose?
por: Vurallı, Doğuş, et al.
Publicado: (2020)

Efficacy and Safety of Leuprolide Acetate 6-Month Depot for the Treatment of Central Precocious Puberty: A Phase 3 Study
por: Klein, Karen O, et al.
Publicado: (2023)

Magnetic resonance imaging based 3-dimensional printed breast surgical guide for breast-conserving surgery in ductal carcinoma in situ: a clinical trial
por: Wu, Zhen-Yu, et al.
Publicado: (2020)

Evaluation of Hypersensitivity Reactions with Leuprolide Acetate and Triptorelin Acetate in Children
por: Metbulut, Azize Pınar, et al.
Publicado: (2021)

Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node–Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer
por: Sohn, Guiyun, et al.
Publicado: (2016)

Survey of clinicians on the use of adjuvant therapy for premenopausal women with breast cancer
por: Lee, Young-Won, et al.
Publicado: (2023)

Endometrial polyp surveillance in premenopausal breast cancer patients using tamoxifen
por: Jeon, Se Jeong, et al.
Publicado: (2017)

Effects of leuprolide acetate on the quality of life of patients with prostate cancer: A prospective longitudinal cohort study
por: Kim, Myung Soo, et al.
Publicado: (2021)

A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients
por: Tunn, Ulf W
Publicado: (2011)

Prediction of Late Breast Cancer-Specific Mortality in Recurrence-Free Breast Cancer Survivors Treated for Five Years with Tamoxifen
por: Baek, Soo Yeon, et al.
Publicado: (2019)

Pseudotumor cerebri in patient on leuprolide acetate for central precocious puberty
por: Omar, Anjumanara Anver, et al.
Publicado: (2020)

Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation
por: Wex, Jaro, et al.
Publicado: (2013)

Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies
por: Spitz, Aaron, et al.
Publicado: (2016)

Factors Predicting Locoregional Recurrence After Neoadjuvant Chemotherapy and Nipple-Sparing/Skin-Sparing Mastectomy With Immediate Breast Reconstruction
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

Leuprolide acetate induces structural and functional recovery of injured spinal cord in rats
por: Díaz Galindo, Carmen, et al.
Publicado: (2015)

In-vitro/In-vivo comparison of leuprolide acetate release from an in-situ forming plga system
por: Mashayekhi, Roya, et al.
Publicado: (2013)

Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer
por: Ryu, Ki-Jin, et al.
Publicado: (2022)

Effect of Tamoxifen on the Risk of Osteoporosis and Osteoporotic Fracture in Younger Breast Cancer Survivors: A Nationwide Study
por: Lee, Jihyoun, et al.
Publicado: (2020)

Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen
por: Lee, Maria, et al.
Publicado: (2020)

A Mobile Technology for Collecting Patient-Reported Physical Activity and Distress Outcomes: Cross-Sectional Cohort Study
por: Jung, Miyeon, et al.
Publicado: (2020)

A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
por: Shiba, Eiichi, et al.
Publicado: (2015)

Survival Outcomes in Premenopausal Patients With Invasive Lobular Carcinoma
por: Yoon, Tae In, et al.
Publicado: (2023)

A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients
por: Shore, Neal, et al.
Publicado: (2019)

Analysis of Adherence, Persistence, and Surgery Among Endometriosis Patients Treated with Leuprolide Acetate Plus Norethindrone Acetate Add-Back Therapy
por: Soliman, Ahmed M., et al.
Publicado: (2016)

Pharmacokinetic–Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats
por: Lee, Dong-Seok, et al.
Publicado: (2018)

Inflammatory myopathy and severe rhabdomyolysis induced by leuprolide acetate therapy for prostate cancer: a case report
por: Bergner, Michael, et al.
Publicado: (2011)

Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial
por: Ohashi, Yasuo, et al.
Publicado: (2017)

A single-dose, randomized, open-labeled, parallel-group study comparing the pharmacokinetics, pharmacodynamics and safety of leuprolide acetate microspheres 3.75 mg and Enantone(®) 3.75 mg in healthy male subjects
por: Hu, Xingjiang, et al.
Publicado: (2022)

Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study
por: Heo, Jung-Yoon, et al.
Publicado: (2017)

Effect of Tamoxifen and Raloxifene on the Proliferative Activity of the Breast Epithelium in Premenopausal Women
por: Lucato, Miliana T, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kggckdvedp2c9vetneg596kbo5